Nova Eye Medical (AU:EYE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Nova Eye Medical Limited reports a significant upswing in FY24 with group sales rising 35% to A$23.3 million, driven by a robust 71% surge in the US market. The company’s EBITDA loss improved by 33%, indicating a promising trend towards profitability, especially in its glaucoma segment. Additionally, the company anticipates further sales growth from proposed Medicare reimbursement rate increases for its products in the USA.
For further insights into AU:EYE stock, check out TipRanks’ Stock Analysis page.
